Herwig Kollaritsch
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ).
Journal: Vaccine
Published: December 10, 2025
Tick-Borne Encephalitis (TBE) - Fundamentals
Journal: Therapeutische Umschau. Revue therapeutique
Published: October 28, 2022
Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel.
Journal: BMC infectious diseases
Published: March 23, 2021
Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.
Journal: Vaccine
Published: November 29, 2018
Vaccination in Multiple Sclerosis: Friend or Foe?
Journal: Frontiers in immunology
Published: September 28, 2018
Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules.
Journal: Scientific reports
Published: August 31, 2017
Guidelines for vaccination of immunocompromised individuals
Journal: Wiener klinische Wochenschrift
Published: May 25, 2016
Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Journal: Vaccine
Published: April 27, 2016
Rotavirus vaccines: a story of success.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: December 19, 2014
A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
Journal: Clinical and vaccine immunology : CVI
Published: September 05, 2014
Last Updated: 09/26/2026